Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Quantum BioPharma Ltd Ordinary Shares - Class B (Sub Voting)

Healthcare CA QNTM

5.7CAD
0.00(0%)

Last update at 2026-06-24T16:46:00Z

Day Range

5.696.20
LowHigh

52 Week Range

2.8552.00
LowHigh

Fundamentals

  • Previous Close 5.70
  • Market Cap27.40M
  • Volume3909
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.75659M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-12.65

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -26.95684M -14.91553M -18.23059M -26.70366M -33.93796M
Minority interest 0.78M 0.71M 0.33M 0.00000M -
Net income -26.17529M -14.20272M -17.90218M -23.60683M -35.28543M
Selling general administrative 12.01M 9.31M 13.20M 15.98M 23.37M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 0.55M 0.49M 2.51M 4.53M -
Ebit - - - - -
Ebitda - - - - -
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -15.31741M -15.88403M -19.57011M -27.42961M -33.74366M
Other operating expenses - - - - -
Interest expense 0.62M 0.05M 0.00030M 0.05M -
Tax provision - - - - -
Interest income 0.24M 0.57M 0.79M 0.37M 0.20M
Net interest income -0.38256M 0.53M 0.79M 0.32M -
Extraordinary items - - - - -1.34747M
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 15.32M 15.88M 19.57M 27.43M -
Cost of revenue - - - - -
Total other income expense net -11.25688M 0.44M 0.55M 0.41M -
Discontinued operations - - - - -
Net income from continuing ops -26.95684M -14.91553M -18.23059M -26.70366M -
Net income applicable to common shares - - - - -35.28543M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 11.16M 17.12M 17.47M 38.41M 62.96M
Intangible assets 4.51M 4.93M 5.36M 12.04M 16.20M
Earning assets - - - - -
Other current assets 2.21M 0.86M - 0.00000M 8.65M
Total liab 6.06M 6.68M 4.57M 7.87M 8.83M
Total stockholder equity 6.92M 11.48M 13.24M 30.54M 54.13M
Deferred long term liab - - - - -
Other current liab - 0.49M 0.03M - -
Common stock - - - 143.41M 152.32M
Capital stock 169.70M 150.47M 137.78M - -
Retained earnings -198.28617M -172.11088M -157.90816M -142.02187M -121.01690M
Other liab - - - - -
Good will - - - - -
Other assets - - - - -
Cash 1.91M 6.00M 2.76M 16.98M 35.26M
Cash and equivalents - - - - -
Total current liabilities 6.06M 6.68M 4.57M 7.83M 8.70M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - 0.30M 0.30M
Short long term debt 1.77M 0.77M 0.30M - -
Short long term debt total - - - - -
Other stockholder equity - - - 0.65M 0.24M
Property plant equipment - - - 0.26M 0.17M
Total current assets 6.48M 12.05M 11.09M 17.85M 45.93M
Long term investments 0.00000M 0.00222M 0.00605M - -
Net tangible assets - - - - -
Short term investments 0.46M 1.20M 0.76M 0.02M 0.16M
Net receivables - - - 0.10M 0.23M
Long term debt - - - - -
Inventory 0.05M 0.12M 0.00000M - -
Accounts payable 1.98M 3.25M 3.24M - -
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 4.68M 5.07M 6.39M - -
Capital lease obligations 0.10M 0.05M 0.04M - -
Long term debt total - - - 0.04M 0.13M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -1.95247M - - - 0.00000M
Change to liabilities - - - - -
Total cashflows from investing activities - -1.50356M -0.26958M 12.12M -
Net borrowings 5.24M - - - -0.12932M
Total cash from financing activities 6.10M 11.62M -3.12659M -2.06931M 38.21M
Change to operating activities - - - - -
Net income -26.17529M -14.91553M -18.23059M -26.70366M -35.28543M
Change in cash -4.09051M 3.24M -14.22343M -18.27917M 17.73M
Begin period cash flow 6.00M - - - 17.52M
End period cash flow 1.91M - - - 35.26M
Total cash from operating activities -8.23701M -6.87648M -10.82726M -28.33327M -20.74622M
Issuance of capital stock 0.34M - - - 38.34M
Depreciation 0.55M 0.49M 2.51M 4.53M 4.05M
Other cashflows from investing activities - -1.50356M -0.26958M 12.49M -
Dividends paid - - - - -
Change to inventory 0.07M - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.00000M 10.67M -2.93754M -1.92624M 0.00000M
Other cashflows from financing activities - - - 0.00000M -
Change to netincome - - - - -
Capital expenditures 0.00000M 0.00000M 0.00000M 0.36M 0.50M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 1.99M 8.76M 1.64M -7.12033M 2.89M
Stock based compensation 2.95M - - - 7.44M
Other non cash items 2.13M - - - 0.02M
Free cash flow -8.23701M - - - -21.24622M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
QNTM
Quantum BioPharma Ltd Ordinary Shares - Class B (Sub Voting)		 - -% 5.70 - - 91.59 2.57 124.30 -2.1599
DRUG
Bright Minds Biosciences Inc		 5.61 6.28% 94.89 - - - 13.50 -0.098
METX
METX		 - -% 1.99 - - - 72.00
TELI
Telescope Innovations Corp.		 0.06 7.23% 0.89 - - 4.32 6.45 4.32 -1.62
DTC
Defence Therapeutics Inc		 -0.03 5.45% 0.52 - - - 89.80 -9.991

Reports Covered

Stock Research & News

View All

Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is headquartered in Toronto, Canada.

Quantum BioPharma Ltd Ordinary Shares - Class B (Sub Voting)

55 University Avenue, Toronto, ON, Canada, M5J 2H7

Key Executives

Name Title Year Born
Mr. Zeeshan Saeed Co-Founder, CEO, & Executive Non-Independent Co-Chairman 1970
Mr. Anthony John Durkacz Co-Founder & Executive Non-Independent Co-Chairman 1976
Mr. Donal Carroll CPA Chief Financial Officer 1977
Mr. Nathan Coyle CPA Controller 1981
Dr. Lakshmi P. Kotra BPHARM, Ph.D. CEO of Lucid & Director 1971
Dr. Andrzej Chruscinski M.D., Ph.D. Vice President of Clinical & Scientific Affairs NA
Dr. Ashwini Joshi Director of Pharmaceutical Development NA
Mr. Jason David Sawyer Head of Finance & Mergers and Acquisitions 1972
Ms. Maryann Adesso Corporate Secretary NA
Randell Mack President of FSD BioSciences NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions